Fabre-Kramer Pharmaceuticals, Inc. and Mission Pharmacal Co. have signed agreements under which Mission will complete the technology transfer to develop and manufacture the registration batches of Fabre-Kramer’s novel antidepressant, Travivo (gepirone HCl) Extended Release Tablets. Data from these batches will be used to support the submission of the NDA Amendment for Travivo to the FDA for review and approval. The companies also expect to enter an agreement for Mission to manufacture and packag...